Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010777

Director sold 67,000 shares at an average $23.36 ($1,564,812)

  • Director acquired 67,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Ballal Rahul D. Director 2024-04-10 Option exercise 10b5-1 +13,600 $12.60 $171,360 35,941 D
Ballal Rahul D. Director 2024-04-10 Sale 10b5-1 −13,600 $21.01 $285,744 22,341 D
Ballal Rahul D. Director 2024-04-11 Option exercise 10b5-1 +48,820 $12.60 $615,132 71,161 D
Ballal Rahul D. Director 2024-04-11 Option exercise 10b5-1 +4,580 $19.68 $90,134 75,741 D
Ballal Rahul D. Director 2024-04-11 Sale 10b5-1 −30,300 $23.14 $701,024 45,441 D
Ballal Rahul D. Director 2024-04-11 Sale 10b5-1 −20,032 $25.00 $500,702 25,409 D
Ballal Rahul D. Director 2024-04-11 Sale 10b5-1 −3,068 $25.21 $77,342 22,341 D
Derivatives
Ballal Rahul D. Director 2024-04-10 Option exercise · Stock Option (right to buy) 10b5-1 −13,600 48,820 D
Ballal Rahul D. Director 2024-04-11 Option exercise · Stock Option (right to buy) 10b5-1 −48,820 0 D
Ballal Rahul D. Director 2024-04-11 Option exercise · Stock Option (right to buy) 10b5-1 −4,580 75,742 D
Open-market sales · 67,000 sh · avg $23.36 · $1,564,812
Loading xslF345X05/form4-04122024_100442.xml…